Developments with 3D bioprinting for novel drug discovery

Aishwarya Satpathy, Pallab Datta, Yang Wu, Bugra Ayan, Ertugrul Bayram, Ibrahim T. Ozbolat

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Although there have been significant contributions from the pharmaceutical industry to clinical practice, several diseases remain unconquered, with the discovery of new drugs remaining a paramount objective. The actual process of drug discovery involves many steps including pre-clinical and clinical testing, which are highly time- and resource-consuming, driving researchers to improve the process efficiency. The shift of modelling technology from two-dimensions (2D) to three-dimensions (3D) is one of such advancements. 3D Models allow for close mimicry of cellular interactions and tissue microenvironments thereby improving the accuracy of results. The advent of bioprinting for fabrication of tissues has shown potential to improve 3D culture models. Areas covered: The present review provides a comprehensive update on a wide range of bioprinted tissue models and appraise them for their potential use in drug discovery research. Expert opinion: Efficiency, reproducibility, and standardization are some impediments of the bioprinted models. Vascularization of the constructs has to be addressed in the near future. While much progress has already been made with several seminal works, the next milestone will be the commercialization of these models after due regulatory approval.

Original languageEnglish (US)
Pages (from-to)1115-1129
Number of pages15
JournalExpert Opinion on Drug Discovery
Volume13
Issue number12
DOIs
StatePublished - Dec 2 2018

Fingerprint

Bioprinting
Drug Discovery
Drug Industry
Expert Testimony
Research Personnel
Technology
Research

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

Satpathy, Aishwarya ; Datta, Pallab ; Wu, Yang ; Ayan, Bugra ; Bayram, Ertugrul ; Ozbolat, Ibrahim T. / Developments with 3D bioprinting for novel drug discovery. In: Expert Opinion on Drug Discovery. 2018 ; Vol. 13, No. 12. pp. 1115-1129.
@article{d75a4927c6654014a46c37ee22c332aa,
title = "Developments with 3D bioprinting for novel drug discovery",
abstract = "Introduction: Although there have been significant contributions from the pharmaceutical industry to clinical practice, several diseases remain unconquered, with the discovery of new drugs remaining a paramount objective. The actual process of drug discovery involves many steps including pre-clinical and clinical testing, which are highly time- and resource-consuming, driving researchers to improve the process efficiency. The shift of modelling technology from two-dimensions (2D) to three-dimensions (3D) is one of such advancements. 3D Models allow for close mimicry of cellular interactions and tissue microenvironments thereby improving the accuracy of results. The advent of bioprinting for fabrication of tissues has shown potential to improve 3D culture models. Areas covered: The present review provides a comprehensive update on a wide range of bioprinted tissue models and appraise them for their potential use in drug discovery research. Expert opinion: Efficiency, reproducibility, and standardization are some impediments of the bioprinted models. Vascularization of the constructs has to be addressed in the near future. While much progress has already been made with several seminal works, the next milestone will be the commercialization of these models after due regulatory approval.",
author = "Aishwarya Satpathy and Pallab Datta and Yang Wu and Bugra Ayan and Ertugrul Bayram and Ozbolat, {Ibrahim T.}",
year = "2018",
month = "12",
day = "2",
doi = "10.1080/17460441.2018.1542427",
language = "English (US)",
volume = "13",
pages = "1115--1129",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "12",

}

Developments with 3D bioprinting for novel drug discovery. / Satpathy, Aishwarya; Datta, Pallab; Wu, Yang; Ayan, Bugra; Bayram, Ertugrul; Ozbolat, Ibrahim T.

In: Expert Opinion on Drug Discovery, Vol. 13, No. 12, 02.12.2018, p. 1115-1129.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Developments with 3D bioprinting for novel drug discovery

AU - Satpathy, Aishwarya

AU - Datta, Pallab

AU - Wu, Yang

AU - Ayan, Bugra

AU - Bayram, Ertugrul

AU - Ozbolat, Ibrahim T.

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: Although there have been significant contributions from the pharmaceutical industry to clinical practice, several diseases remain unconquered, with the discovery of new drugs remaining a paramount objective. The actual process of drug discovery involves many steps including pre-clinical and clinical testing, which are highly time- and resource-consuming, driving researchers to improve the process efficiency. The shift of modelling technology from two-dimensions (2D) to three-dimensions (3D) is one of such advancements. 3D Models allow for close mimicry of cellular interactions and tissue microenvironments thereby improving the accuracy of results. The advent of bioprinting for fabrication of tissues has shown potential to improve 3D culture models. Areas covered: The present review provides a comprehensive update on a wide range of bioprinted tissue models and appraise them for their potential use in drug discovery research. Expert opinion: Efficiency, reproducibility, and standardization are some impediments of the bioprinted models. Vascularization of the constructs has to be addressed in the near future. While much progress has already been made with several seminal works, the next milestone will be the commercialization of these models after due regulatory approval.

AB - Introduction: Although there have been significant contributions from the pharmaceutical industry to clinical practice, several diseases remain unconquered, with the discovery of new drugs remaining a paramount objective. The actual process of drug discovery involves many steps including pre-clinical and clinical testing, which are highly time- and resource-consuming, driving researchers to improve the process efficiency. The shift of modelling technology from two-dimensions (2D) to three-dimensions (3D) is one of such advancements. 3D Models allow for close mimicry of cellular interactions and tissue microenvironments thereby improving the accuracy of results. The advent of bioprinting for fabrication of tissues has shown potential to improve 3D culture models. Areas covered: The present review provides a comprehensive update on a wide range of bioprinted tissue models and appraise them for their potential use in drug discovery research. Expert opinion: Efficiency, reproducibility, and standardization are some impediments of the bioprinted models. Vascularization of the constructs has to be addressed in the near future. While much progress has already been made with several seminal works, the next milestone will be the commercialization of these models after due regulatory approval.

UR - http://www.scopus.com/inward/record.url?scp=85058212682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058212682&partnerID=8YFLogxK

U2 - 10.1080/17460441.2018.1542427

DO - 10.1080/17460441.2018.1542427

M3 - Review article

C2 - 30384781

AN - SCOPUS:85058212682

VL - 13

SP - 1115

EP - 1129

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 12

ER -